NASDAQ:APTO - Aptose Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.50 +0.34 (+8.17 %)
(As of 06/19/2018 06:00 AM ET)
Previous Close$4.50
Today's Range$4.22 - $4.55
52-Week Range$1.07 - $4.55
Volume1.31 million shs
Average Volume586,457 shs
Market Capitalization$136.86 million
P/E Ratio-8.65
Dividend YieldN/A
Beta2.37
Aptose Biosciences logoAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive APTO News and Ratings via Email

Sign-up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APTO
CUSIPN/A
Phone64-7479-9828

Debt

Debt-to-Equity RatioN/A
Current Ratio7.51
Quick Ratio7.51

Price-To-Earnings

Trailing P/E Ratio-8.65
Forward P/E Ratio-6.25
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.39 per share
Price / Book11.54

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-11,660,000.00
Net MarginsN/A
Return on Equity-136.61%
Return on Assets-119.69%

Miscellaneous

Employees23
Outstanding Shares32,900,000

Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) released its quarterly earnings results on Tuesday, March, 27th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. View Aptose Biosciences' Earnings History.

What price target have analysts set for APTO?

3 brokerages have issued 12-month price objectives for Aptose Biosciences' stock. Their forecasts range from $6.00 to $7.00. On average, they expect Aptose Biosciences' share price to reach $6.3333 in the next year. View Analyst Ratings for Aptose Biosciences.

Who are some of Aptose Biosciences' key competitors?

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the folowing people:
  • Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
  • Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
  • Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
  • Mr. Peter Murray, Director of Clinical Devel.

Has Aptose Biosciences been receiving favorable news coverage?

News headlines about APTO stock have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aptose Biosciences earned a news impact score of 0.15 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.32 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Aptose Biosciences' major shareholders?

Aptose Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Ladenburg Thalmann Financial Services Inc. (0.19%). View Institutional Ownership Trends for Aptose Biosciences.

Which institutional investors are buying Aptose Biosciences stock?

APTO stock was purchased by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc.. View Insider Buying and Selling for Aptose Biosciences.

How do I buy shares of Aptose Biosciences?

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aptose Biosciences' stock price today?

One share of APTO stock can currently be purchased for approximately $4.50.

How big of a company is Aptose Biosciences?

Aptose Biosciences has a market capitalization of $136.86 million. The biotechnology company earns $-11,660,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Aptose Biosciences employs 23 workers across the globe.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 5955 AIRPORT ROAD SUITE 228, MISSISSAUGA A6, L4V 1R9. The biotechnology company can be reached via phone at 64-7479-9828 or via email at [email protected]


MarketBeat Community Rating for Aptose Biosciences (APTO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  376
MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe APTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.